Collaboration to explore the potential of creating new generation aantibody-drug conjugates with SynTracer from Biosion® internalization platform and ImmunoGen’s proprietary linker-payload technology
NEWARK, Del., December 13, 2022 /PRNewswire/ — Biosion United States of America, Inc. (Biosion), a global biotechnology research and development company, today announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc. (Nasdaq: IMGN ), a leading developer of next-generation drug ADCs. In the joint research effort, Biosion will leverage its proprietary SynTracer® high-throughput endocytosis (HT) platform to generate highly selective antibodies for targets assigned by each company, and ImmunoGen will provide its proprietary linker-payload technology to create new ADCs.
“We are excited about our new joint research effort with ImmunoGen, a world-renowned leader in ADCs,” he said. Hugh DavisPh.D., Chief Operating Officer and President of Biosion United States of AmericaInc. “This collaboration will leverage each company’s strengths; ImmunoGen’s expertise in linkers and payloads combined with Biosion’s SynTracer® HT endocytosis platform with the aim of identifying new treatments for tumors of solid tumors”.
Biosion is a global clinical-stage biotechnology company developing antibody-based therapeutics to improve patient outcomes for the treatment of immune and oncological diseases. Founded in 2017, Biosion has built a pipeline of innovative biologics through its proprietary internally derived technologies, including the H³ antibody discovery platform, SynTracer® high-throughput endocytosis platform and bispecific Flexibody™ platform. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in Phase 2 for severe asthma and entering Phase 2 for atopic dermatitis. Biosion and partners plan to advance additional immuno-oncology biologics and antibody drug conjugates into clinical trials for oncology indications over the next year. Biosion operates in the United States, AustraliaAnd China.
Learn more about Biosion at www.biosion.com.
About SynTracer® High-throughput endocytosis (HT) platform.
SynTracer® The HT Endocytosis Platform is Biosion’s antibody discovery platform that enables the rapid identification of antibodies with high endocytosis rates, providing promising candidates for antibody drug conjugates. The SynTracer® The HT Endocytosis Platform is also uniquely positioned to identify superior antibodies for use with other modalities such as siRNAs, oligonucleotides, radioisotopes, and immunostimulatory agents.
Media and investor contact
Senior Director, Business Development
E-mail: [email protected]
SOURCE Biosion, Inc.